#Edaravone
LightNews LightNews
bild.bsky.social
🧠 Yeni ALS ilacı nörodejenerasyonu teşhis etmeye yardımcı olmuş.

Bilim insanları, oksidatif stresi tespit etmek için ALS tedavisinde kullanılan bir ilaç olan edaravone ile pozitron emisyon tomografisi (PET) kullanmışlar.
Repurposed ALS drug becomes imaging probe to help diagnose neurodegeneration
See how scientists at St. Jude Children’s Research Hospital use positron emission tomography scanning and an ALS drug edaravone to detect neurodegeneration
www.stjude.org
March 10, 2025 at 12:07 PM
imatus.bsky.social
🧪 #Paper: “Exploring Nano-Delivery Systems to Enhance the Edaravone Performance in Amyotrophic Lateral Sclerosis Treatment.”

🤝 Collaboration: iMATUS, IDIS, CIQUP-IMS, i4HB & UCIBIO.

🔗 www.mdpi.com/1422-0067/26...

#Biomaterial #DrugDelivery #Nanoparticles #Pharmasky
Exploring Nano-Delivery Systems to Enhance the Edaravone Performance in Amyotrophic Lateral Sclerosis Treatment
Edaravone is one of the treatment options for Amyotrophic Lateral Sclerosis, but its therapeutic efficacy is limited due to the incapacity to cross the blood–brain barrier, as well as its short life s...
www.mdpi.com
February 28, 2025 at 8:22 AM
stjuderesearch.bsky.social
Scientists repurposed the ALS drug edaravone as an imaging probe for neurodegenerative diseases. Using PET, they can now visualize oxidative stress, a key factor in conditions such as ALS and stroke. ow.ly/qfJL50VaYwb
March 5, 2025 at 2:00 PM
alsadvocacy.bsky.social
Well that was interesting. European researcher asked MT P presenter about contrast in findings w their study that showed no diff w edaravone. Speaker wouldn’t address. Researcher pressed. It will be an interesting offline conversation perhaps. #alsmndsymp
December 6, 2024 at 4:28 PM
christine520.bsky.social
Since 2017 I have been on the 10 day regimen of infusions of edaravone. It has helped me and now I feel validated by these studies.
Please pass this article on to any ALS patient considering and/or newly diagnosed.

alsnewstoday.com/news/edaravo...
Edaravone is more than antioxidant in ALS treatment: Early study
Edaravone may exert its neuroprotective effects in ALS by also correcting the abnormal localization of TDP-43, a key molecular feature of ALS, a study says.
alsnewstoday.com
April 4, 2025 at 7:52 PM
journal-cer.bsky.social
📢New article alert

New Short Report on compares disease progression milestone-free time between #ALS patients treated with IV edaravone and those not treated..

🔗Read here: becarispublishing.com/doi/10.57264...

#ALS #RealWorldData #ALSResearch #OpenAccess #JCER
Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis
Aim: To estimate time-to-progression milestones in people with amyotrophic lateral sclerosis (PALS) treated versus not treated with intravenous (IV) edaravone (Radicava® IV, Mitsubishi Tanabe Pharma A...
becarispublishing.com
January 29, 2025 at 2:20 PM
gregoryai.bsky.social
New clinical trial
A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)

#ClinicalTrials #MultipleSclerosis #MSchat #Neurology
A Phase 3, Multi-center, Open-label, Safety Extension Study of Oral Edaravone Administered Over 96 Weeks in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Clinical trial related to Multiple Sclerosis.
clinicaltrials.gov
January 25, 2026 at 8:40 AM
bild.bsky.social
Birlikte antioksidan ve anti-enflamatuar etkiye sahip olan edaravone ve dexborneol kombinasyonunun inme sonuçlarını önemli ölçüde iyileştirebileceğini bulmuşlar.
bild.bsky.social Çağsı @bild.bsky.social · Feb 20
Sinir koruyucu bir ilaç kombinasyonu inme sonuçlarını iyileştirebilirmiş. Beyindeki hücreleri koruyan hızlı etkili bir ilaç kombinasyonu, inme sonrası hastaların semptomlarını iyileştirmeye yardımcı olabilirmiş. 👇 +

jamanetwork.com/journals/jam...
February 20, 2024 at 11:22 AM
thedailypub.bsky.social
Fighting antibiotic resistance just got a boost! Combining antioxidants like NAC and Edaravone with antibiotics helped curb resistance in Pseudomonas biofilms. This study found fewer resistant mutations and lower antibiotic doses needed. Could antioxidants be key in the battle against superbugs?
The impact of antioxidant-ciprofloxacin combinations on the evolution of antibiotic resistance in Pseudomonas aeruginosa biofilms.
Published in NPJ biofilms and microbiomes
doi.org
January 1, 2025 at 2:00 AM
esiode.bsky.social
📃Scientific paper: Safety and efficacy of edaravone in patients with amyotrophic lateral sclerosis: a systematic review...

➡️ Continued on ES/IODE

August 26, 2024 at 4:02 PM
quollhorreur.bsky.social
Ocrelizumab - multiple schlerosis
Edaravone - ALS and stroke
Pembrolizumab - melanoma, lung, head & neck, cervical and some types of breast cancer
Atezolizumab - urothelial, lung and liver cancers

And MFKing NIVO (nivolumab)
March 2, 2025 at 4:58 AM
int-pharmacy.bsky.social
New hope for stomach cancer? Study shows edaravone+dasatinib boosts senescence, cuts AGS cell migration via p53, MMP2—may prevent metastasis. #CancerTherapy #Senescence
www.rimpacts.com/rd/p?c=10045... 📄DOI: doi.org/10.2174/0109...
Molecular and Biochemical Evidence of Edaravone's Impact on Dasatinib-Induced Ags Cell Senescence: A Promising Strategy for Gastric Cancer Therapy
New hope for stomach cancer? Study shows edaravone+dasatinib boosts senescence, cuts AGS cell migration via p53, MMP2—may prevent metastasis. #CancerTherapy #Senescence
www.rimpacts.com
January 7, 2026 at 8:46 AM
sciencex.bsky.social
A repurposed ALS drug, edaravone, now serves as a PET imaging probe, enhancing early detection of oxidative stress-related neurodegenerative diseases like Alzheimer's and ALS. doi.org/g866h8
Repurposed amyotrophic lateral sclerosis drug becomes imaging probe to help diagnose neurodegeneration
Positron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative advance from scientists at St. Jude Children's Research Hospital is enhancing the technique's ability to check for signs of neurological disease.
medicalxpress.com
March 5, 2025 at 7:03 PM
bild.bsky.social
Beyindeki hücreleri koruyan hızlı etkili bir ilaç kombinasyonu, inme sonrası hastaların semptomlarını iyileştirmeye yardımcı olabilirmiş. Edaravone ve dexborneol kombinasyonu. Dil altına yerleştirilebiliyor. Bilinci kapalı olması önemli değil.

jamanetwork.com/journals/jam...
February 21, 2024 at 4:13 PM
rridrobot.bsky.social
A paper using RRID:AB_2263076 from @proteintech.bsky.social was just published in Metabolic Brain Disease. We value the author's support of reproducibility. #ReproducibleResearch #ReproducibleResearch #ReproducibleResearch
ROS-responsive dextran-benzeneboronic acid pinacol ester micelles encapsulating edaravone for the treatment and mechanism of cerebral ischemia-reperfusion injury
doi.org
May 18, 2025 at 7:01 AM
medicine.stitches.today
Edaravone dexborneol enhances functional independence post-stroke without escalating safety risks, especially in patients with initial mismatch scores.

by Wang C, Gu H (...) Wang Y et 32 al. in BMJ #MedSky

👉 get more here

📖 read the article: https://www.bmj.com/content/392/bmj-2025-086850
January 16, 2026 at 2:28 AM
alsadvocacy.bsky.social
We’ve seen two conflicting sets of results of edaravone trials. Brooks is trying to find a flaw in the Ferrer trial. Van den Berg insists on the quality of his trial. Does it really work? We see docs trying to ask Qs to challenge the Euro trial.
December 6, 2024 at 7:24 PM
l2plabs.bsky.social
NeuroSense Unveils Accelerated, Capital-Efficient Strategy to Advance PrimeC Toward Potential Approval in ALS
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's differentiation, shorten the time to potential commercialization, and significantly...
dlvr.it
August 31, 2026 at 12:49 PM
esiode.bsky.social
📃Scientific paper: Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study

Ref.: BioMed Central, 2022

➡️ Continued on ES/IODE
July 17, 2026 at 6:02 PM
babygoldie.bsky.social
[3/4] trials are progressing. Its combination with edaravone is expected to provide new treatments. Up to now, the cumulative investment in research and development of this drug is approximately 16.6 million yuan. There are uncertainties in
July 15, 2026 at 8:53 AM
babygoldie.bsky.social
[3/4] trials are progressing. Its combination with edaravone is expected to provide new treatments. Up to now, the cumulative investment in research and development of this drug is approximately 16.6 million yuan. There are uncertainties in
July 15, 2026 at 8:53 AM
babygoldie.bsky.social
[2/4] Trial Approval Notice" for HRS-8829 Concentrated Solution for Injection, and will conduct clinical trials for the indication of "combined with Edaravone Injection for the treatment of acute ischemic stroke." HRS-8829 is a small molecule drug whose single-agent phase I clinical
July 15, 2026 at 8:53 AM
babygoldie.bsky.social
[2/4] Trial Approval Notice" for HRS-8829 Concentrated Solution for Injection, and will conduct clinical trials for the indication of "combined with Edaravone Injection for the treatment of acute ischemic stroke." HRS-8829 is a small molecule drug whose single-agent phase I clinical
July 15, 2026 at 8:53 AM
mndaus-research.bsky.social
Plenty of caveats but a decent number of participants and to my non-expert eye a reasonable analysis;
Longer disease progression milestone-free time in people with ALS treated vs not treated with iv edaravone: results from an administrative claims analysis becarispublishing.com/doi/10.57264...
Longer disease progression milestone-free time in people with amyotrophic lateral sclerosis treated versus not treated with intravenous edaravone: results from an administrative claims analysis
Aim: To estimate time-to-progression milestones in people with amyotrophic lateral sclerosis (PALS) treated versus not treated with intravenous (IV) edaravone (Radicava® IV, Mitsubishi Tanabe Pharma A...
becarispublishing.com
February 5, 2025 at 4:22 AM
gregoryai.bsky.social
https://gregory-ms.com/articles/289858/
Edaravone promotes motoneuron survival and functional recovery after brachial plexus root avulsion and reimplantation in rats: Involvement of SIRT1/TFEB pathway

#MSchat #MS #Neurology #MultipleSclerosis #NeuroSky #NeuroSkyence
December 9, 2024 at 10:50 AM